PUBLISHER: DelveInsight | PRODUCT CODE: 1605438
PUBLISHER: DelveInsight | PRODUCT CODE: 1605438
Parkinson's Disease Market Insight, Epidemiology And Market Forecast - 2034
Key Highlights:
- According to DelveInsight's estimates, in 2023, there were approximately 2,718 thousand diagnosed prevalent cases of Parkinson's disease in the 7MM. Of these, the United States accounted for 45% of the cases, while Japan and Germany represented 9% and 18% of the cases, respectively.
- DelveInsight's epidemiology model projects that Parkinson's disease cases in the US included nearly 695 thousand males and 517 thousand females in 2023. The model anticipates an increase throughout the study period, with male cases outpacing female cases by 2034, reflecting a higher prevalence among men.
- In 2023, among EU4 and UK, the highest Parkinson's disease cases in Stage III, totaling nearly 409 thousand followed by approximately 406 thousand cases in Stage II. The Stage V had the least cases accounting for 53 thousand cases.
- The Parkinson's disease market is poised for steady growth, with a compound annual growth rate (CAGR) expected to remain strong from 2024 to 2034. This growth will be driven primarily by advancements in diagnostic techniques, increased awareness of the condition, and a rising number of reported cases.
- According to DelveInsight's analysis, the Parkinson's disease market in the 7MM was valued at approximately USD 3,218 million in 2023. Over the forecast period from 2024 to 2034, this market is projected to grow at a significant CAGR.
- Pharma giants are actively working on better treatment options. Late-stage therapies include Supernus Pharmaceutical and Britannia Pharmaceutical's SPN-830 (apomorphine infusion pump), AbbVie's tavapadon, Pharma Two B's P2B001 (extended-release pramipexole and rasagiline), Mitsubishi Tanabe Pharma Corporation/NeuroDerm's ND0612 (levodopa/carbidopa), and Annovis Bio's Buntanetap/ANVS402/ANVS401, among others.
DelveInsight's "Parkinson's disease - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The Parkinson's disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Parkinson's disease market size from 2020 to 2034. The Report also covers current Parkinson's disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Disease Understanding and Treatment Algorithm
Parkinson's disease Overview
According to the Parkinson's Foundation, Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing (dopaminergic) neurons in a specific area of the brain called the substantia nigra. Because Parkinson's disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson's disease: Stage I, Stage II, Stage III, Stage IV, and Stage V.
Parkinson's disease diagnosis
Diagnosing Parkinson's disease can be challenging, as there is no definitive test for the condition. Instead, the diagnosis is typically based on a combination of medical history, symptoms, physical and neurological examinations, and sometimes additional tests. MRI may be used only to exclude other causes. DaTscan, an imaging test, can assist in confirming the diagnosis by assessing dopamine levels in the brain. Additionally, advancements in neuroimaging studies, including transcranial Doppler ultrasonography, PET, single-photon emission computed tomography (SPECT), morphometric MRI studies, tractography, functional MRI, and perfusion imaging, are being used to differentiate idiopathic Parkinson's disease from other parkinsonian disorders. Radionuclide imaging modalities like PET and SPECT, using a dopamine transporter ligand, have become the best approach to assess dopamine metabolism and deficiency.
Parkinson's disease treatment
Treatment involves pharmacologic approaches, typically with levodopa preparations prescribed with or without other medications, MAO-B inhibitors, COMT inhibitors, amantadine, and anticholinergics, and non-pharmacologic approaches (such as exercise, physical, occupational, and speech therapies). Approaches such as deep brain stimulation and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremors, worsening symptoms when the medication wears off, and dyskinesia.
The management of Parkinson's disease aims at improving the quality of life for individuals affected by the condition with symptomatic relief. There are several medications approved by the US FDA such as, XADAGO, DUOPA/DUODOPA, INBRIJA, ONGENTYS, and others are also being used to treat motor and non-motor symptoms associated with Parkinson's disease.
Parkinson's Disease Epidemiology
As the market is derived using a patient-based model, the Parkinson's disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Parkinson's Disease, Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease, Age-specific Diagnosed Prevalent Cases of Parkinson's Disease, Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease, Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease, and Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
- According to DelveInsight's epidemiology model, the total diagnosed prevalent cases of Parkinson's disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the forecast period (2024-2034) due to increasing awareness, aging population, and advancement of diagnostic procedures.
- In the 7MM, Japan accounted for approximately 258 thousand cases diagnosed prevalent cases of Parkinson's disease in 2023.
- Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Parkinson's disease with nearly 495 thousand cases in 2023 followed by France accounting for approximately 277 thousand cases. On the other hand, Spain accounted for the least with nearly 149 thousand cases.
- In 2023, Japan accounted for approximately 135 thousand cases in males and 123 thousand cases in females, based on gender-specific diagnosed prevalent cases of Parkinson's disease. These cases are expected to increase during the forecast period.
- In the US, nearly 19 thousand cases were diagnosed with Parkinson's disease in the age group =49 years, 215 thousand cases in 50-64 years, 449 thousand cases in 65-74 years, and 527 thousand cases in =75 years in 2023.
- Among the stage-specific diagnosed prevalent cases of Parkinson's disease in Japan, there were approximately 9 thousand cases for Stage I, 40 thousand cases for Stage II, 107 thousand cases for Stage III, 70 thousand cases for Stage IV, and 31 thousand cases for Stage V in 2023.
- In Japan, there were approximately 73 thousand cases of psychosis associated with Parkinson's disease in 2023.
- In the assessment done by DelveInsight, the estimated Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US were nearly 508 thousand in 2023.
Parkinson's Disease Drug Chapters
The drug chapter segment of the Parkinson's disease report encloses a detailed analysis of Parkinson's disease off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Parkinson's disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals
CREXONT is a novel oral formulation of carbidopa/levodopa (CD/LD) that combines immediate-release (IR) granules and extended-release (ER) pellets. This prescription medication is used to treat Parkinson's disease, Parkinson's disease caused by brain infection or inflammation, and Parkinson's disease-like symptoms resulting from carbon monoxide or manganese poisoning in adults. The ER beads in CREXONT consist of levodopa (LD), coated with a sustained-release polymer for slow drug release, a mucoadhesive polymer to ensure the granules remain at the absorption site longer, and an enteric coating to prevent premature disintegration in the stomach. This formulation is distinct from RYTARY (carbidopa/levodopa) extended-release capsules, Amneal's extended-release CD/LD treatment for Parkinson's disease approved by the US FDA in 2015.
In February 2024, Amneal Pharmaceuticals entered into an exclusive licensing agreement with Zambon Biotech for IPX203 (CREXONT) in the European Union.
In August 2024, the US FDA approved CREXONT extended-release capsules for the treatment of Parkinson's disease.
Emerging Drugs
SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals
SPN-830 (apomorphine infusion device) is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease patients that are not adequately controlled with oral levodopa and one or more adjunct Parkinson's disease medications. SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14-18 h. The target infusion rate ranged between 3 mg and 8 mg per h. The thin, small needle applied underneath the skin is usually placed on the abdomen or upper thigh. Such administration has the potential to be less invasive, with fewer injection sites, and is more convenient than Supernus Pharmaceutical's already approved product APOKYN, which mimics the action of dopamine in the brain, is intended to reduce off periods on demand, and is administered under the skin.
In April 2024, the US FDA issued a complete response letter (CRL) for Supernus Pharmaceuticals' NDA for SPN-830.
Additionally, in August 2024, Supernus Pharmaceuticals resubmitted its NDA for the apomorphine infusion device (SPN-830) to provide continuous treatment for motor fluctuations (OFF episodes) in Parkinson's disease.
Parkinson's Disease Market Outlook
Parkinson's disease is a progressively worsening neurodegenerative disorder with an unclear cause and pathogenesis. Its global burden is increasing, driven by aging populations and environmental factors. Classic symptoms include motor issues like bradykinesia, rigidity, tremors, and postural instability, along with non-motor symptoms such as depression, cognitive impairment, and autonomic disturbances, which significantly affect quality of life. Diagnosing Parkinson's is challenging due to symptom overlap with other movement disorders, with imaging like PET scans aiding in diagnosis.
While no curative therapy exists, various pharmacological and non-pharmacological treatments are used to manage symptoms. Carbidopa/levodopa remains the most effective treatment, with new formulations like CREXONT (approved in August 2024) and RYTARY (approved in 2015) offering symptom relief. DUOPA, a carbidopa/levodopa enteral suspension, and HARUROPI TAPE (ropinirole HCL), a transdermal patch, provide additional options, though innovations have been limited.
The Parkinson's disease treatment landscape faces significant unmet needs, particularly for curative and disease-modifying therapies. Better motor symptom control, especially for tremors, gait, balance, and psychosis treatment, remains a critical challenge.
Nevertheless, a plethora of medications is under development. These include drugs that specifically target a-synuclein pathology, widely considered to be the driver of neurodegeneration in Parkinson's disease. These drugs offer hope for disease-modifying agents in the short- to medium-term future. In combination with several regenerative approaches, including stem cells and gene therapies, therapeutics for Parkinson's disease are likely to see significant advances over the coming years, with several novel, effective options likely to become available in the foreseeable future.
The current emerging pipeline is robust, late-stage drugs expected to enter the Parkinson's disease market during the forecast period include Supernus Pharmaceuticals/Britannia Pharmaceuticals' SPN-830 (apomorphine infusion pump), AbbVie's tavapadon, Pharma Two B's P2B001 (extended-release pramipexole and rasagiline), and Mitsubishi Tanabe Pharma Corporation (NeuroDerm)'s ND0612 (levodopa/carbidopa), among others. The approval of these therapies could significantly impact market dynamics, although their success rates remain uncertain.
- The market size of Parkinson's disease in the US was approximately USD 1,883 million in 2023, which is anticipated to increase due to the increasing awareness of the disease and the launch of the emerging therapy.
- The total market size of EU4 and the UK was calculated to be approximately USD 988 million in 2023, which was nearly 31% of the total market revenue for the 7MM.
- According to DelveInsight's estimates, among EU4 and the UK, Germany accounted for the highest market with approximately USD 390 million in 2023, followed by France with approximately USD 218 million in the respective year, and the UK with USD 130 million in 2023. These numbers are projected to increase during the forecast period (2024-2034).
- In 2023, the total market size of Parkinson's disease was approximately USD 348 million in Japan which is anticipated to increase during the forecast period.
- According to DelveInsight's analysis, among the currently approved therapies, the majority of the market share was of others and combination therapies, with a revenue of approximately USD 2,210 million in 2023.
- With the expected launch of upcoming therapies, such as SPN-830, Tavapadon, P2B001, ND0612, among others, the total market size of Parkinson's disease is expected to show change in the upcoming years.
Parkinson's Disease Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, SPN-830 in the US is expected to be launched by 2025 with a peak share of 2.50%. Tavapadon is anticipated to take 7 years to peak with a medium uptake.
Parkinson's Disease Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Parkinson's disease emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Parkinson's disease evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Parkinson's Foundation, Miami, US; Stanford University, US; Pacific Health Research and Education Institute, Honolulu, HI US; Department of Neurology, St. Josef-Hospital, Ruhr University Bochum, Germany; Sante publique France, French Public Health Agency, Saint-Maurice, France; Sante publique France, French Public Health Agency, Saint-Maurice, France; Universitario Central de Asturias, Spain; and Department of Neurology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Parkinson's disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, descriptive overview of Parkinson's disease, explaining its causes, signs and symptoms, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the Parkinson's disease market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Parkinson's disease market.
Parkinson's disease Report Insights
- Patient Population
- Therapeutic Approaches
- Parkinson's Disease Pipeline Analysis
- Parkinson's Disease Market Size and Trends
- Existing and Future Market Opportunity
Parkinson's Disease Report Key Strengths
- 11 years Forecast
- The 7MM Coverage
- Parkinson's Disease Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Parkinson's Disease Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions:
Market Insights
- What was the Parkinson's Disease market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Parkinson's Disease total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Parkinson's Disease market size during the forecast period (2024-2034)?
- At what CAGR, the Parkinson's Disease market is expected to grow at the 7MM level during the forecast period (2024-2034)?
- What would be the Parkinson's Disease market outlook across the 7MM during the forecast period (2024-2034)?
- What would be the Parkinson's Disease market growth till 2034 and what will be the resultant market size in the year 2034?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What is the disease risk, burden, and unmet needs of Parkinson's Disease?
- What is the historical Parkinson's Disease patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient population of Parkinson's disease at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Parkinson's Disease?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Parkinson's Disease during the forecast period (2024-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for the treatment of Parkinson's Disease along with the approved therapy?
- What are the current treatment guidelines for the treatment of Parkinson's Disease in the US, Europe, And Japan?
- What are the Parkinson's Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Parkinson's Disease?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Parkinson's Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Parkinson's Disease therapies?
- What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Parkinson's Disease and their status?
- What are the key designations that have been granted for the emerging therapies for Parkinson's Disease?
- What are the 7MM historical and forecasted market of Parkinson's Disease?
Reasons to Buy:
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Parkinson's Disease Market.
- Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
- Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions:
1. What is the forecast period covered in the report?
The Parkinson's Disease Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.
2. Who are the key players in the Parkinson's Disease market?
The Parkinson's Disease market is quite robust. The major players are Supernus Pharmaceuticals, Britannia Pharmaceuticals, AbbVie , Pharma Two B, Mitsubishi Tanabe Pharma Corporation, NeuroDerm and others which are currently developing drugs for the treatment of Parkinson's disease.
3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.
4. What is the key driver of the Parkinson's Disease market?
The increase in diagnosed prevalent cases of Parkinson's Disease and the launch of emerging therapies are attributed to be the key drivers for increasing the Parkinson's disease market.
5. What is the expected impact of emerging therapies or advancements in Parkinson's Disease treatment on the market?
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Parkinson's disease treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Parkinson's Disease market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Parkinson's disease Market Overview at a Glance
- 3.1. Market Share (%) Distribution of Parkinson's disease in 2020
- 3.2. Market Share (%) Distribution of Parkinson's disease in 2034
4. Methodology of Parkinson's disease Epidemiology and Market
5. Executive Summary of Parkinson's Disease
6. Key Events
7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Classification
- 7.3. Signs and Symptoms
- 7.4. Risk Factors
- 7.5. Pathophysiology
- 7.6. Diagnosis
- 7.6.1. Biomarker
- 7.6.2. Diagnostic Guidelines
- 7.6.2.1. American Academy of Family Physicians
- 7.6.2.2. European Federation of Neurological Societies/Movement Disorder Society- European Section (EFNS/MDS-ES) Recommendations for the Diagnosis of Parkinson's Disease
- 7.6.2.3. The National Institute for Health and Care Excellence (NICE): Recommendation for Diagnosis of Parkinson's Disease
- 7.6.2.4. Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease
- 7.6.3. Diagnostic Algorithm
- 7.6.4. Differential Diagnosis
- 7.7. Treatment
- 7.7.1. Treatment Algorithm
- 7.7.2. Treatment Guidelines
- 7.7.2.1. National Institute for Health and Care Excellence (NICE): Recommendation for Parkinson's disease
- 7.7.2.2. American Academy of Neurology (AAN) Guidelines for Treatment of Early Parkinson's Disease
- 7.7.2.3. Clinical Practice Guidelines by the NHS Spain
- 7.7.2.4. Clinical Practice Guidelines by the Japanese Society of Neurology (JSN)
- 7.7.2.5. Guideline of the German Society for Neurology
8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale: The 7MM
- 8.2.1. Diagnosed Prevalent Cases of Parkinson's Disease
- 8.2.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease
- 8.2.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease
- 8.2.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease
- 8.2.5. Diagnosed Prevalent Cases of Psychosis in Parkinson's Disease
- 8.2.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease
- 8.3. Total Diagnosed Prevalent Cases of Parkinson's Disease in the 7MM
- 8.4. The United States
- 8.4.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in the US
- 8.4.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US
- 8.4.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US
- 8.4.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US
- 8.4.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the US
- 8.4.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US
- 8.5. EU4 and the UK
- 8.5.1. Germany
- 8.5.1.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Germany
- 8.5.1.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany
- 8.5.1.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany
- 8.5.1.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany
- 8.5.1.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Germany
- 8.5.1.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Germany
- 8.5.2. France
- 8.5.2.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in France
- 8.5.2.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in France
- 8.5.2.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in France
- 8.5.2.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in France
- 8.5.2.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in France
- 8.5.2.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in France
- 8.5.3. Italy
- 8.5.3.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Italy
- 8.5.3.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy
- 8.5.3.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy
- 8.5.3.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy
- 8.5.3.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Italy
- 8.5.3.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Italy
- 8.5.4. Spain
- 8.5.4.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Spain
- 8.5.4.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain
- 8.5.4.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain
- 8.5.4.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain
- 8.5.4.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Spain
- 8.5.4.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Spain
- 8.5.5. The United Kingdom
- 8.5.5.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in the UK
- 8.5.5.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK
- 8.5.5.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK
- 8.5.5.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK
- 8.5.5.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the UK
- 8.5.5.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the UK
- 8.5.1. Germany
- 8.6. Japan
- 8.6.1. Total Diagnosed Prevalent Cases of Parkinson's Disease in Japan
- 8.6.2. Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan
- 8.6.3. Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan
- 8.6.4. Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan
- 8.6.5. Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Japan
- 8.6.6. Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Japan
9. Patient Journey
10. Marketed Therapies
- 10.1. Key Cross Competition of Marketed Drugs
- 10.2. XADAGO/EQUFINA (Safinamide): Newron Pharmaceuticals/ Zambon/Supernus Pharmaceuticals/Eisai
- 10.2.1. Product Description
- 10.2.2. Regulatory Milestones
- 10.2.3. Other Development Activities
- 10.2.4. Clinical Trial Information
- 10.2.5. Safety and Efficacy
- 10.3. NOURIANZ/NOURIAST (Istradefylline): Kyowa Kirin
- 10.3.1. Product Description
- 10.3.2. Regulatory Milestones
- 10.3.3. Other Development Activities
- 10.3.4. Clinical Trial Information
- 10.3.5. Safety and Efficacy
- 10.4. DUOPA/DUODOPA (Carbidopa and Levodopa-ES): AbbVie
- 10.4.1. Production Description
- 10.4.2. Regulatory Milestones
- 10.4.3. Other Development Activities
- 10.4.4. Clinical Trial Information
- 10.4.5. Safety and Efficacy
- 10.5. INBRIJA (Levodopa): Acorda Therapeutics/Esteve Pharmaceuticals
- 10.5.1. Production Description
- 10.5.2. Regulatory milestones
- 10.5.3. Other Development Activities
- 10.5.4. Clinical Trial Information
- 10.5.5. Safety and Efficacy
- 10.6. GOCOVRI (Amantadine): Supernus Pharmaceuticals
- 10.6.1. Product Description
- 10.6.2. Other Development Activities
- 10.6.3. Regulatory Milestones
- 10.6.4. Clinical Trial Information
- 10.6.5. Safety and Efficacy
- 10.7. ONGENTYS (Opicapone): Neurocrine Biosciences/BIAL/Ono Pharmaceutical
- 10.7.1. Product Description
- 10.7.2. Regulatory Milestones
- 10.7.3. Other Development Activities
- 10.7.4. Clinical Trial Information
- 10.7.5. Safety and Efficacy
- 10.8. HARUROPI TAPE (Ropinirole HCL): Hisamitsu Pharmaceutical/Kyowa Kirin
- 10.8.1. Production Description
- 10.8.2. Regulatory Milestones
- 10.8.3. Other Development Activities
- 10.8.4. Safety and Efficacy
- 10.9. NEUPRO/ Rotigotine Transdermal: UCB
- 10.9.1. Product Description
- 10.9.2. Regulatory Milestone
- 10.9.3. Other Development Activities
- 10.9.4. Safety and Efficacy
- 10.1. RYTARY (Carbidopa and Levodopa): Amneal Pharmaceuticals
- 10.10.1. Product Description
- 10.10.2. Regulatory Milestone
- 10.10.3. Other Development Activities
- 10.10.4. Clinical Trial Information
- 10.10.5. Safety and Efficacy
- 10.11. ABBV951/ PRODUODOPA/ VYALEV (Foscarbidopa/ Foslevodopa): AbbVie
- 10.11.1. Product Description
- 10.11.2. Regulatory Milestone
- 10.11.3. Other Development Activities
- 10.11.4. Clinical Trials Information
- 10.11.5. Safety and Efficacy
- 10.12. CREXONT/IPX203: Amneal Pharmaceuticals
- 10.12.1. Product Description
- 10.12.2. Regulatory Milestone
- 10.12.3. Other Development Activities
- 10.12.4. Clinical Trial Information
- 10.12.5. Safety and Efficacy
11. Emerging Drug Profiles
- 11.1. Key Cross Competition
- 11.2. Solengepras (CVN424): Cerevance
- 11.2.1. Product Description
- 11.2.2. Other Developmental Activities
- 11.2.3. Clinical Trials Information
- 11.2.4. Safety and Efficacy
- 11.2.5. Analyst Views
- 11.3. Minzasolmin (UCB0599): UCB Biopharma SRL/Novartis
- 11.3.1. Product Description
- 11.3.2. Other Developmental Activities
- 11.3.3. Clinical Trials Information
- 11.3.4. Safety and Efficacy
- 11.3.5. Analyst Views
- 11.4. Buntanetap (ANVS401/Posiphen): Annovis Bio
- 11.4.1. Product Description
- 11.4.2. Other Development Activities
- 11.4.3. Clinical Trial Information
- 11.4.4. Safety and Efficacy
- 11.4.5. Analyst Views
- 11.5. SPN-830 (Apomorphine Infusion): Supernus Pharmaceuticals, Inc./ Britannia Pharmaceutical
- 11.5.1. Product Description
- 11.5.2. Other Development Activities
- 11.5.3. Clinical Trials Information
- 11.5.4. Safety and Efficacy
- 11.5.5. Analyst Views
- 11.6. P2B001 (Extended-release Pramipexole and Rasagiline): Pharma Two B
- 11.6.1. Product Description
- 11.6.2. Other Development Activities
- 11.6.3. Clinical Trials Information
- 11.6.4. Safety and Efficacy
- 11.6.5. Analyst Views
- 11.7. ND0612 (Levodopa/Carbidopa): Mitsubishi Tanabe Pharma (NeuroDerm)
- 11.7.1. Product Description
- 11.7.2. Other Development Activities
- 11.7.3. Clinical Trials Information
- 11.7.4. Safety and Efficacy
- 11.7.5. Analyst Views
- 11.8. Tavapadon: AbbVie/Cerevel Therapeutics, LLC
- 11.8.1. Product Description
- 11.8.2. Other Development Activities
- 11.8.3. Clinical Trial Information
- 11.8.4. Safety and Efficacy
- 11.8.5. Analyst Views
12. Parkinson's disease: Market Analysis
- 12.1. Key Findings
- 12.2. Market Outlook
- 12.3. Key Market Forecast Assumptions
- 12.4. Conjoint Analysis
- 12.5. Total Market Size of Parkinson's Disease in the 7MM
- 12.6. Market Size of Parkinson's Disease by Therapies in the 7MM
- 12.7. Market Size of Parkinson's Disease in the United States
- 12.7.1. Total Market Size of Parkinson's Disease
- 12.7.2. Market Size of Parkinson's Disease by Therapies in the United States
- 12.8. Market Size of Parkinson's Disease in EU4 and the UK
- 12.8.1. Market Size of Parkinson's Disease in Germany
- 12.8.1.1. Total Market Size of Parkinson's Disease
- 12.8.1.2. Market Size of Parkinson's Disease by Therapies in Germany
- 12.8.2. Market Size of Parkinson's Disease in France
- 12.8.2.1. Total Market Size of Parkinson's Disease
- 12.8.2.2. Market Size of Parkinson's Disease by Therapies in France
- 12.8.3. Market Size of Parkinson's Disease in Italy
- 12.8.3.1. Total Market Size of Parkinson's Disease
- 12.8.3.2. Market Size of Parkinson's Disease by Therapies in Italy
- 12.8.4. Market Size of Parkinson's Disease in Spain
- 12.8.4.1. Total Market Size of Parkinson's Disease
- 12.8.4.2. Market Size of Parkinson's Disease by Therapies in Spain
- 12.8.5. Market Size of Parkinson's Disease in the UK
- 12.8.5.1. Total Market Size of Parkinson's Disease
- 12.8.5.2. Market Size of Parkinson's Disease by Therapies in the UK
- 12.8.1. Market Size of Parkinson's Disease in Germany
- 12.9. Market Size of Parkinson's Disease in Japan
- 12.9.1. Total Market Size of Parkinson's Disease
- 12.9.2. Market Size of Parkinson's Disease by Therapies in Japan
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
- 16.1. The United States
- 16.1.1. Center for Medicare and Medicaid Services (CMS)
- 16.2. In EU4 and the UK
- 16.2.1. Germany
- 16.2.2. France
- 16.2.3. Italy
- 16.2.4. Spain
- 16.2.5. The United Kingdom
- 16.3. Japan
- 16.3.1. MHLW
17. Appendix
- 17.1. Bibliography
- 17.2. Acronyms and Abbreviations
- 17.3. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Tables
- Table 1: Summary of Market and Epidemiology (2020-2034)
- Table 2: Key Events for Parkinson's Disease
- Table 3: Signs and Symptoms of Parkinson's Disease
- Table 4: Differential Diagnosis of Parkinsonism (1/2)
- Table 5: Differential Diagnosis of Parkinsonism (2/2)
- Table 6: Potential Benefits and Harms of Dopamine Agonists, Levodopa, and MAO B inhibitors
- Table 7: Potential Benefits and Harms of Dopamine Agonists, COMT Inhibitors, and Amantadine
- Table 8: Pharmacological Management of Non-motor Symptoms (1/2)
- Table 9: Pharmacological Management of Non-motor Symptoms (2/2)
- Table 10: Nonpharmacological Management of Motor and Non-motor Symptoms (1/2)
- Table 11: Nonpharmacological Management of Motor and Non-motor Symptoms (2/2)
- Table 12: AAN Guidelines for the Treatment of Early Parkinson's Disease (1/2)
- Table 13: AAN Guidelines for the Treatment of Early Parkinson's Disease (2/2)
- Table 14: NHS Spain - Motor Symptoms Recommendations for Treatment of Parkinson's Disease
- Table 15: NHS Spain - Non-motor Symptoms Recommendations for Treatment of Parkinson's Disease
- Table 16: NHS Spain - Recommendations for Treatment of Parkinson's Disease (Non-pharmacological)
- Table 17: Recommendations for Treatment of Parkinson's Disease - Speech Therapy
- Table 18: Recommendations for Treatment of Parkinson's Disease - Nutrition and Diet
- Table 19: Recommendations for Treatment of Parkinson's Disease by JSN - 2011 Update (1/2)
- Table 20: Recommendations for Treatment of Parkinson's Disease by JSN - 2011 Update (2/2)
- Table 21: Total Diagnosed Prevalent Cases of Parkinson's Disease in the 7MM (2020-2034)
- Table 22: Total Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Table 23: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Table 24: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Table 25: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Table 26: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the US (2020-2034)
- Table 27: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US (2020-2034)
- Table 28: Total Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 29: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 30: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 31: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 32: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 33: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 34: Total Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Table 35: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Table 36: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Table 37: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Table 38: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Germany (2020-2034)
- Table 39: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Germany (2020-2034)
- Table 40: Total Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Table 41: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Table 42: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Table 43: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Table 44: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in France (2020-2034)
- Table 45: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in France (2020-2034)
- Table 46: Total Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Table 47: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Table 48: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Table 49: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Table 50: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Italy (2020-2034)
- Table 51: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Italy (2020-2034)
- Table 52: Total Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Table 53: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Table 54: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Table 55: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Table 56: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Spain (2020-2034)
- Table 57: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Spain (2020-2034)
- Table 58: Total Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Table 59: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Table 60: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Table 61: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Table 62: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the UK (2020-2034)
- Table 63: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the UK (2020-2034)
- Table 64: Total Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Table 65: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Table 66: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Table 67: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Table 68: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Japan (2020-2034)
- Table 69: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Japan (2020-2034)
- Table 70: Comparison of Marketed Drugs
- Table 71: XADAGO/EQUFINA (safinamide), Clinical Trial Description, 2024
- Table 72: NOURIANZ/NOURIAST (istradefylline), Clinical Trial Description, 2024
- Table 73: DUOPA/DUODOPA (carbidopa and levodopa-ES), Clinical Trial Description, 2024
- Table 74: INBRIJA (levodopa), Clinical Trial Description, 2024
- Table 75: GOCOVRI (amantadine), Clinical Trial Description, 2024
- Table 76: ONGENTYS (opicapone), Clinical Trial Description, 2024
- Table 77: RYTARY (carbidopa and levodopa), Clinical Trial Description, 2024
- Table 78: ABBV-951 (foscarbidopa/foslevodopa), Clinical Trial Description, 2024
- Table 79: IPX203, Clinical Trial Description, 2024
- Table 80: Comparison of Emerging Drugs
- Table 81: Solengepras (CVN424), Clinical Trial Description, 2024
- Table 82: Minzasolmin (UCB0599), Clinical Trial Description, 2024
- Table 83: Buntanetap (ANVS401/Posiphen), Clinical Trial Description, 2024
- Table 84: SPN-830 (apomorphine infusion), Clinical Trial Description, 2024
- Table 85: P2B001 (extended-release pramipexole and rasagiline), Clinical Trial Description, 2024
- Table 86: ND0612 (levodopa/carbidopa), Clinical Trial Description, 2024
- Table 87: Tavapadon, Clinical Trial Description, 2024
- Table 88: Key Market Forecast Assumptions for SPN-830 (Apomorphine Infusion Pump)
- Table 89: Key Market Forecast Assumptions for Tavapadon
- Table 90: Key Market Forecast Assumptions for ABBV-951 (foscarbidopa/foslevodopa)
- Table 91: Key Market Forecast Assumptions for CREXONT (carbidopa/levodopa extended-release)
- Table 92: Key Market Forecast Assumptions for P2B001 (extended-release pramipexole and rasagiline)
- Table 93: Key Market Forecast Assumptions for ND0612 (levodopa/carbidopa)
- Table 94: Key Market Forecast Assumptions for Buntanetap (ANVS401/posiphen)
- Table 95: Key Market Forecast Assumptions for Solengepras (CVN424)
- Table 96: Key Market Forecast Assumptions for Minzasolmin (UCB0599)
- Table 97: Total Market Size of Parkinson's Disease in the 7MM (2020-2034)
- Table 98: Market Size of Parkinson's Disease by Therapies in the 7MM (2020-2034)
- Table 99: Total Market Size of Parkinson's Disease in the US (2020-2034)
- Table 100: Market Size of Parkinson's Disease by Therapies in the United States (2020-2034)
- Table 101: Total Market Size of Parkinson's Disease in EU4 and the UK (2020-2034)
- Table 102: Market Size of Parkinson's Disease by Therapies in EU4 and the UK (2020-2034)
- Table 103: Total Market Size of Parkinson's Disease in Germany (2020-2034)
- Table 104: Market Size of Parkinson's Disease by Therapies in Germany (2020-2034)
- Table 105: Total Market Size of Parkinson's Disease in France (2020-2034)
- Table 106: Market Size of Parkinson's Disease by Therapies in France (2020-2034)
- Table 107: Total Market Size of Parkinson's Disease in Italy (2020-2034)
- Table 108: Market Size of Parkinson's Disease by Therapies in Italy (2020-2034)
- Table 109: Total Market Size of Parkinson's Disease in Spain (2020-2034)
- Table 110: Market Size of Parkinson's Disease by Therapies in Spain (2020-2034)
- Table 111: Total Market Size of Parkinson's Disease in the UK (2020-2034)
- Table 112: Market Size of Parkinson's Disease by Therapies in the UK (2020-2034)
- Table 113: Total Market Size of Parkinson's Disease in Japan (2020-2034)
- Table 114: Market Size of Parkinson's Disease by Therapies in Japan (2020-2034)
List of Figures
- Figure 1: Classification of Parkinson's Disease
- Figure 2: Clinical Manifestations in Parkinson's Disease
- Figure 3: Risk Factors Involved in Parkinson's Disease
- Figure 4: Genes Involved in Parkinson's Disease
- Figure 5: Mechanisms of Neurodegeneration in Parkinson's Disease
- Figure 6: QSBB Criteria for the Diagnosis of Parkinson's Disease
- Figure 7: MDS Clinical Diagnostic Criteria for Parkinson's Disease
- Figure 8: AAFP Diagnostic Algorithm for Parkinson's Disease
- Figure 9: Treatment for Parkinson's Disease
- Figure 10: Mechanism of Action of Levodopa
- Figure 11: Dopamine Agonists for the Treatment of Parkinson's Disease
- Figure 12: Treatment Algorithm for Parkinson's Disease
- Figure 13: Total Diagnosed Prevalent Cases of Parkinson's Disease in the 7MM (2020-2034)
- Figure 14: Total Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Figure 15: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Figure 16: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Figure 17: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the US (2020-2034)
- Figure 18: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the US (2020-2034)
- Figure 19: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the US (2020-2034)
- Figure 20: Total Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 21: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 22: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 23: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 24: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 25: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 26: Total Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Figure 27: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Figure 28: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Figure 29: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Germany (2020-2034)
- Figure 30: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Germany (2020-2034)
- Figure 31: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Germany (2020-2034)
- Figure 32: Total Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Figure 33: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Figure 34: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Figure 35: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in France (2020-2034)
- Figure 36: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in France (2020-2034)
- Figure 37: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in France (2020-2034)
- Figure 38: Total Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Figure 39: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Figure 40: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Figure 41: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Italy (2020-2034)
- Figure 42: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Italy (2020-2034)
- Figure 43: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Italy (2020-2034)
- Figure 44: Total Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Figure 45: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Figure 46: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Figure 47: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Spain (2020-2034)
- Figure 48: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Spain (2020-2034)
- Figure 49: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Spain (2020-2034)
- Figure 50: Total Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Figure 51: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Figure 52: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Figure 53: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in the UK (2020-2034)
- Figure 54: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in the UK (2020-2034)
- Figure 55: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in the UK (2020-2034)
- Figure 56: Total Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Figure 57: Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Figure 58: Age-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Figure 59: Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease in Japan (2020-2034)
- Figure 60: Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease in Japan (2020-2034)
- Figure 61: Diagnosed Prevalent Cases of MCI due to Parkinson's Disease in Japan (2020-2034)
- Figure 62: Patient Journey
- Figure 63: Total Market Size of Parkinson's Disease in the 7MM (2020-2034)
- Figure 64: Market Size of Parkinson's Disease by Therapies in the 7MM (2020-2034)
- Figure 65: Total Market Size of Parkinson's Disease in the US (2020-2034)
- Figure 66: Market Size of Parkinson's Disease by Therapies in the United States (2020-2034)
- Figure 67: Total Market Size of Parkinson's Disease in EU4 and the UK (2020-2034)
- Figure 68: Market Size of Parkinson's Disease by Therapies in EU4 and the UK (2020-2034)
- Figure 69: Total Market Size of Parkinson's Disease in Germany (2020-2034)
- Figure 70: Market Size of Parkinson's Disease by Therapies in Germany (2020-2034)
- Figure 71: Total Market Size of Parkinson's Disease in France (2020-2034)
- Figure 72: Market Size of Parkinson's Disease by Therapies in France (2020-2034)
- Figure 73: Total Market Size of Parkinson's Disease in Italy (2020-2034)
- Figure 74: Market Size of Parkinson's Disease by Therapies in Italy (2020-2034)
- Figure 75: Total Market Size of Parkinson's Disease in Spain (2020-2034)
- Figure 76: Market Size of Parkinson's Disease by Therapies in Spain (2020-2034)
- Figure 77: Total Market Size of Parkinson's Disease in the UK (2020-2034)
- Figure 78: Market Size of Parkinson's Disease by Therapies in the UK (2020-2034)
- Figure 79: Total Market Size of Parkinson's Disease in Japan (2020-2034)
- Figure 80: Market Size of Parkinson's Disease by Therapies in Japan (2020-2034)
- Figure 81: SWOT Analysis
- Figure 82: Unmet Needs
- Figure 83: Health Technology Assessment
- Figure 84: Reimbursement Process in the United States
- Figure 85: Reimbursement Process in Germany
- Figure 86: Reimbursement Process in France
- Figure 87: Reimbursement process in Italy
- Figure 88: Reimbursement Process in Spain
- Figure 89: Reimbursement Process in the United Kingdom
- Figure 90: Reimbursement Process in Japan
